


In the Claims:

This listing of claims will replace all prior versions and listings of claims in this application.

1 (Original). A compound of formula (I)



wherein

one of X and Y is silicon, and the other is carbon or silicon;

Z is oxygen, sulphur or $-N(R)-$, wherein R is hydrogen or alkyl;

R^1 is hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy or cycloalkyl; and

R^2 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,
-alkyl-cycloalkyl, -alkyl-heterocycloalkyl, -alkyl-aryl or -alkyl-heteroaryl;
or a pharmaceutically acceptable salt thereof.

2 (Previously presented). The compound according to claim 1, wherein X and Y are each silicon.

3 (Previously presented). The compound according to claim 1, wherein Z is oxygen.

4 (Previously presented). The compound according to claim 1, wherein R^1 is hydrogen or alkyl.

5 (Previously presented). The compound according to claim 4, wherein R^1 is methyl.

6 (Previously presented). The compound according to claim 1, wherein R^2 is aryl, $-CH_2-$ cycloalkyl, $-CH_2-$ aryl, $-CH_2-$ heterocycloalkyl or $-CH_2-$ heteroaryl.


7 (Previously presented). The compound according to claim 6, wherein R^2 is optionally substituted phenyl.

8 (Previously presented). The compound according to claim 7, wherein R^2 is phenyl substituted with one, two or three alkyl groups.

9 (Previously presented). The compound according to claim 1, which is 5-[(3,5,5,8,8-pentamethyl-5,8-disila-5,6,7,8-tetrahydro-2-naphthyl)methyl]-*N*-(2,4,6-trimethoxyphenyl)furan-2-carboxamide.

10 (Canceled).

11 (Previously presented). A pharmaceutical composition comprising a compound of formula (I)



wherein

one of X and Y is silicon, and the other is carbon or silicon;


Z is oxygen, sulphur or $-N(R)-$, wherein R is hydrogen or alkyl;

R^1 is hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy or cycloalkyl; and

R^2 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,

-alkyl-cylcoalkyl, -alkyl-heterocycloalkyl, -alkyl-aryl or -alkyl-heteroaryl;
or a pharmaceutically acceptable salt thereof;
and a pharmaceutically acceptable diluent or carrier.

12 (Currently amended). A method for ~~the treatment or prevention of a disease or condition~~
treating reproductive disorders and hormone dependent tumors associated with GnRH wherein
said method comprises administering a compound of formula (I)



wherein

one of X and Y is silicon, and the other is carbon or silicon;
Z is oxygen, sulphur or -N(R)-, wherein R is hydrogen or alkyl;
R¹ is hydrogen, halogen, alkyl, alkanyl, alkynyl, alkoxy or cycloalkyl; and
R² is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,
-alkyl-cylcoalkyl, -alkyl-heterocycloalkyl, -alkyl-aryl or -alkyl-heteroaryl;
or a pharmaceutically acceptable salt thereof;
to a patient in need of such treatment.

13 (Currently amended). The method according to claim 12, for the treatment of tumors or
prevention of progression of cancer.

14 (Cancelled).

15 (Previously presented). The method according to claim 12, for the treatment or prevention of a fertility disorder.

16 – 21 (Cancelled).